sotorasib
A case series published last month shows the KRAS-inhibiting cancer drug can also improve symptoms in patients with severe blood vessel overgrowth disorders.
Results from early phase trials of three different combination strategies involving a KRAS G12C inhibitor showed improvement over monotherapy approaches.
FDA Denies Full Approval of Amgen's Lumakras, Requests Additional Confirmatory Study
The FDA declined to convert Lumakras' 2021 accelerated approval in KRAS G12C-mutated NSCLC to full approval, asking for further study data instead.
UK's MHRA Conditionally Approves Mirati's Krazati for Advanced KRAS-Mutated NSCLC
The agency granted Mirati a license for the drug in previously treated, advanced KRAS G12C-mutated NSCLC based on data from the KRYSTAL-1 trial.
Blincyto sales continue to grow following positive data last year in acute lymphoblastic leukemia and an update to NCCN guidelines for pediatric patients.